Developed by Indian firm Epigeneres Biotech in 2021, the “first pan-cancer blood test” predicted the formation of tumors for at least 25 types of cancer, including breast, pancreatic, lung, and colorectal, according to the New York Post.
The trial results, which involved 1,000 patients split evenly between those affected by cancer and those unaffected, were “radically successful,” according to Ashish Tripathi, the founder and CEO of Tzar Labs and chairman of Epigeneres Biotech. “Not only can I actually detect it at this stage — I can actually tell you which cancer and where it is forming, straight from a blood test,” Tripathi revealed in an interview with medical advocate Deepak Chopra.
March 28, 2023
What sets this test apart from others is its focus on stem cells with a genetic marker for cancer, rather than indicators for full-blown tumor cells that could already be present. It is this ability to detect cancer in its earliest stages, before the formation of tumors, that makes the test the “holy grail” of cancer detection, according to Dr. Sherif Raouf, a gastrointestinal cancer specialist who will lead a trial at St. Bartholomew’s Hospital in London. “To have one blood test to detect the presence of cancer at the earliest stage — or even before it develops — could save many lives. This could be a game-changer,” Raouf said to The Express.
HORRIFIC FOOTAGE EMERGES: FRANTIC RESCUE EFFORTS AFTER RUSSIAN MISSILES HIT UKRAINIAN CITY (WATCH)
Not only is the test beneficial in the early detection of cancer, but it can also be used to help those who have already been diagnosed by indicating which organ(s) cancer cells are targeting, thus helping doctors stop the spread of cancer before it becomes more difficult to treat. This life-saving potential makes the test revolutionary and a potential game-changer in the fight against cancer.
Discover alternative ideas that will make you think
Engage in mind bending debate
Earn points, rise in rank, have fun
